Full-Time
Product Manager
Clinical Workflows
Flatiron Health
1,001-5,000 employees
Cancer-focused EHR platform for real-world data
No salary listed
New York, NY, USA
Hybrid
Three office days per week are required.
Bachelor's
 Product (1) |
|---|
Get referred to Flatiron Health
See people who can refer or advise you
- At least 3 years of proven product management experience, including independently scoping requirements, translating end-to-end user journeys into technical backlogs, and leading cross-functional teams from concept to launch.
- A BA/BS degree in a technical field or equivalent practical experience in a software, SaaS, or healthcare technology environment.
- The ability to evaluate, scope, and identify applications of artificial intelligence and machine learning to complex data and workflow challenges.
- The ability to shape intricate, multi-step workflows into thoughtful, intuitive user interfaces.
- A customer-centric B2B/enterprise mindset with the ability to understand customer needs and translate them into clear product strategy.
- Organizational, analytical, and prioritization skills, including interpreting data insights, navigating tradeoffs, and managing execution across competing priorities with high autonomy.
- Define and execute product strategy in collaboration with engineering, design, and cross-functional teams to deliver high-impact solutions.
- Own the product lifecycle for user-facing applications supporting clinical oncology workflows from concept through launch and iteration.
- Lead the design, development, and rollout of data-driven products that streamline clinical operations and reinforce safe, high-quality care delivery.
- Drive product discovery through stakeholder partnership, customer user research, and data and clinical insights to inform product priorities and roadmaps.
- Evaluate, prototype, and ship new capabilities, including exploring how artificial intelligence and intelligent workflows can reduce cognitive burden and improve clinical efficiency.
- Lead the team in translating complex clinical context, technical constraints, and business goals into clear product requirements and making strategic tradeoffs to deliver safe, intuitive solutions.
- Ensure solutions adhere to safety, regulatory, and compliance standards while delivering an intuitive user experience for care teams.
- Establish key performance indicators for clinical workflow efficiency, usability, and product adoption, and hold the cross-functional pod accountable to measurable patient and business outcomes.
- Communicate product vision, strategy, and roadmap to internal teams, customers, and vendor partners.
- Experience working in healthcare technology, clinical workflows, or directly with clinical users and stakeholders.
- Experience identifying, scoping, or shipping artificial intelligence and machine learning capabilities within complex SaaS products.
- Experience working in highly regulated or compliance-driven environments.
Flatiron Health focuses on cancer care with a specialized Electronic Health Record (EHR) platform. It helps community oncologists, academic institutions, hospitals, life sciences researchers, and regulatory bodies manage patient information, share data, and run real-world data-driven studies. The product works by providing a cancer-specific EHR and real-time data integration that connects various stakeholders to enable smarter research and better patient outcomes. It differentiates itself through its narrow focus on oncology, real-world data capabilities, and collaboration across providers, researchers, and regulators, supported by a strong emphasis on data quality (e.g., recognition like the American Cancer Society Data Impact Award). The company aims to improve cancer care and accelerate research by turning real-world data into actionable insights and enabling evidence generation for new treatments.
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
$313.1M
Headquarters
New York City, New York
Founded
2012
Get referred to Flatiron Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- Abbott and Natera integrations expanded OncoEMR workflow lock-in in March and November 2025.
- ASCO 2026 featured 49+ acceptances, signaling strong scientific credibility and customer traction.
- Nathan Hubbard became CEO on August 6 2025, aligning commercialization with Roche's strategy.
What critics are saying
- Paradigm bought Flatiron's clinical research business on December 4 2025, shrinking core revenue.
- Headcount fell to 1,550 by March 2026, down 23.8% from 2023.
- Tempus, IQVIA, and ConcertAI attack Flatiron's data moat with faster AI products.
What makes Flatiron Health unique
- Roche-backed Flatiron spans 1,600 sites, 4,700 providers, and 5M+ patient journeys.
- VALID framework, published April 20 2026, makes AI-extracted oncology data auditable.
- Flatiron Telescope, launched May 19 2026, turns natural-language queries into cohort answers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Work/life autonomy via flexible work hours and flexible paid time off
Generous parental leave (16 weeks for either parent)
Transition back to work program following parental leave
Child and caregiver travel benefits for new parents
Backup child care
Weekly meditation sessions
Flatiron-sponsored fitness classes
Weekly massages and manicures available onsite (employee funded)
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↓ -1%Flatiron Health has announced 25-plus research acceptances at the American Society of Clinical Oncology Annual Meeting, taking place from 29 May to 2 June 2026 in Chicago. The presentations include 14 Flatiron-authored posters covering digital twin modelling, physician adoption of clinical trials and recurrence risk prediction. The announcement follows the launch of Flatiron Telescope, a multi-agent adaptive analytics platform designed to help life sciences teams identify patients faster and generate oncology insights on demand. The platform will be demonstrated at the company's booth. Research highlights include digital twin modelling for treatment prediction in non-small cell lung cancer, large-language model analysis of how clinical trial findings translate to practice, and real-world treatment patterns in platinum-resistant ovarian cancer. The work spans advanced AI capabilities and real-world evidence validation across multiple cancer types.
Flatiron Health has launched Flatiron Telescope, an AI-powered platform that enables life sciences teams and researchers to generate oncology insights in minutes using natural language queries. The platform translates complex inclusion and exclusion criteria into patient cohorts without requiring coding skills. Built on over 15 years of longitudinal data from more than 4,700 providers across 1,600 sites, Flatiron Telescope covers roughly two in five cancer patients and spans over 5 million patient journeys across the US, UK, Germany and Japan. The platform's multi-agent adaptive analytics engine allows users to dynamically stratify cohorts by biomarkers, treatment history and lines of therapy whilst generating real-time feasibility assessments. The platform aims to democratise access to oncology insights across clinical development, real-world evidence and commercial functions, reducing the time from hypothesis to insight from months to minutes.
Flatiron Health has published the Validation of Accuracy for LLM/ML-Extracted Information and Data (VALID) Framework in the Journal of Clinical Oncology Clinical Cancer Informatics. The framework represents the first peer-reviewed approach to evaluating real-world oncology data extracted by large language models and machine learning. The VALID Framework employs three pillars: variable-level performance metrics benchmarking LLM extraction against human abstraction, automated verification checks identifying data inconsistencies, and replication analyses confirming LLM-extracted results match established clinical findings. Flatiron applies this framework to datasets with longitudinal records across millions of patients and over 1.5 billion data points. The framework aims to establish industry standards for AI-extracted clinical data quality whilst maintaining rigour for high-stakes cancer care and drug development decisions.
Abbott Laboratories has integrated its Precision Oncology portfolio into Flatiron Health's OncoEMR platform, giving over 1,600 community cancer centres and 4,700 providers direct access to tests including Oncotype DX and OncoExTra within their clinical workflows. The integration allows clinicians to order and receive cancer diagnostic results without leaving their electronic medical records system. This follows Abbott's recent integration of its Libre continuous glucose monitoring data into Epic's health record system, part of a broader strategy to embed its products into clinical workflows. Whilst the move may enhance test adoption and streamline administrative tasks, analysts suggest it is unlikely to significantly shift Abbott's near-term investment narrative, which remains centred on its core devices business and managing margin pressure from tariffs and foreign exchange headwinds.
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR(R) platform. * 1 hr ago PR Newswire ABBOTT PARK, Ill. and NEW YORK, March 30, 2026 * Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment decisions * Allows oncologists to order tests and view results directly in the clinical workflow ABBOTT PARK, Ill. and NEW YORK, March 30, 2026 /PRNewswire/ - Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR(R), Flatiron's cloud-based Electronic Medical Record (EMR) platform. Through this integration, oncology providers can now digitally order Abbott tests - individually or in combination - and receive status updates and results directly within their existing OncoEMR clinical workflow. Available Abbott tests include the Oncotype DX Breast Recurrence Score(R), OncoExTra(R), Oncodetect(R), and Riskguard(R) tests, enabling clinicians to access the comprehensive portfolio through a single, unified experience. This approach supports more informed treatment decisions across multiple stages of cancer care while helping reduce administrative burden and keeping the focus on patient care. The integration expands access to Abbott's Precision Oncology tests across Flatiron's national network of more than 1,600 community cancer care centers, where 4,700 providers deliver care and where most cancer care in the U.S. takes place. "We're focused on making it easier for clinicians to access the right information at the right moment of care," said Quincy Weatherspoon, VP and GM of Point of Care Solutions, Flatiron Health. "By integrating Abbott's Precision Oncology portfolio directly into OncoEMR, we're reducing friction in the workflow and helping providers move faster - from test ordering to treatment decisions. This is what it looks like to bring more connected, data-driven care to the point of care." "For community oncology practices, where most cancer care is delivered, this removes a key barrier to accessing our portfolio at the point of care, helping accelerate treatment decisions and enabling more informed, personalized patient care," said Brian Baranick, vice president, Precision Oncology, Abbott. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Its 122,000 colleagues serve people in more than 160 countries. Connect with Mycarrollcountynews at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, Mycarrollcountynews continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. SOURCE Abbott